Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection.
Larsson
C
C
Department of Medical Microbiology, Lund University.
Stålhammar-Carlemalm
M
M
Lindahl
G
G
D000818:Animals; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000276:immunology* / Q000302:isolation & purification; D001428:Bacterial Vaccines / Q000302:isolation & purification / Q000494:pharmacology*; D007117:Immunization, Secondary; D008297:Male; D008565:Membrane Proteins / Q000276:immunology / Q000302:isolation & purification; D051379:Mice; D008809:Mice, Inbred C3H; D012703:Serotyping; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000145:classification / Q000276:immunology* / Q000472:pathogenicity; D014611:Vaccination
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D008565:Membrane Proteins; C081277:Rib protein, Streptococcus agalactiae